On July 19, 2023, the Third People’s Hospital of Shenzhen (hereinafter referred to as Shenzhen Third Hospital) and Shenzhen New Industries Biomedical Engineering Co., Ltd. (hereinafter referred to as Snibe) successfully held an exchange seminar and a signing ceremony of strategic cooperation on “Industry-University-Research-Hospital-Application”. 

Based on Shenzhen Third Hospital’s advantages of cutting-edge academic research and medical resources, and the platform advantages of Shenzhen Third Hospital, the two sides will formally carry out all-round co-operation on the research and development of in vitro diagnostic medical devices and scenario applications. Jointly building a platform for high-level clinical research, academic exchanges and education to drive the development by innovation, and to make contribution to health and human life.

Exchange of cutting-edge academic research

At the beginning, Academician Lu Hongzhou and his team from Shenzhen Third Hospital and Shenzhen National Clinical Research Center for Infectious Diseases visited Snibe. Professor Zheng Mingbin, Dr Zhao Pengfei from Hepatitis Institute of Shenzhen Third Hospital and Snibe Reagent R&D team conducted a discussion and exchange of information on the main line of diagnosis and treatment of Mycobacterium tuberculosis, focusing on the development needs of diagnosis of tuberculosis disease, the research progress of rapid and instantaneous detection technology in the clinic, and other aspects, which provided important references to the research and development of the related technology and clinical transformation and application.

Signing of the strategic cooperation

To responded to the "14th Five-Year Plan" for the Development of the Pharmaceutical Industry, "Healthy China 2030" Planning Programme, Shenzhen Third Hospital and Snibe signed the cooperation agreement. Through this cooperation, the two sides will establish a mechanism for interaction between R&D and clinics that deeply excavate clinical needs, identify clinical dilemmas, and carry out all-round cooperation in the fields of disease diagnosis and treatment, medical technology development, R&D of in vitro diagnostic products, technology industrialization, and joint cultivation of talents, so as to form a benign cycle.